Therapeutic strategies to improve drug delivery across the blood-brain barrier

Neurosurgical Focus

Volumn 38, Issue 3, 2015, Pages

  Azad, Tej D ^a   Pan, James ^a   Connolly, Ian D ^a   Remington, Austin ^a   Wilso n, Christy M ^a   Grant, Gerald A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Convection enhanced delivery; Focused ultrasound; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; BLOOD BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84929643070     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.12.FOCUS14758     Document Type: Article

References (130)

1. Abbott NJ, Revest PA: Control of brain endothelial permeability. Cerebrovasc Brain Metab Rev 3:39-72, 1991.
2. Abbott NJ, Rönnbäck L, Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41-53, 2006.
3. Agarwal S, Hartz AM, Elmquist WF, Bauer B: Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 17:2793-2802, 2011.
4. Allen C, Opyrchal M, Aderca I, Schroeder MA, Sarkaria JN, Domingo E, et al: Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther 20:444-449, 2013.
5. Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P, et al: Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 8:213-220, 2008 (Erratum in Expert Opin Biol Ther 8:855, 2008).
6. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I: Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A 89:8472-8476, 1992.
7. Arvanitis CD, Livingstone MS, Vykhodtseva N, McDannold N: Controlled ultrasound-induced blood-brain barrier disruption using passive acoustic emissions monitoring. PLoS ONE 7:e45783, 2012.
8. Aryal M, Vykhodtseva N, Zhang YZ, Park J, McDannold N: Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model. J Control Release 169:103-111, 2013.
9. Ashby LS, Ryken TC: Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus 20(4):E3, 2006.
10. Baseri B, Choi JJ, Tung YS, Konofagou EE: Multi-modality safety assessment of blood-brain barrier opening using focused ultrasound and definity microbubbles: a short-term study. Ultrasound Med Biol 36:1445-1459, 2010.
11. Beccaria K, Canney M, Goldwirt L, Fernandez C, Adam C, Piquet J, et al: Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits. J Neurosurg 119:887-898, 2013.
12. Begley DJ, Brightman MW: Structural and functional aspects of the blood-brain barrier. Prog Drug Res 61:39-78, 2003.
13. Bellavance MA, Blanchette M, Fortin D: Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 10:166-177, 2008.
14. Bernal GM, LaRiviere MJ, Mansour N, Pytel P, Cahill KE, Voce DJ, et al: Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine (Lond Print) 10:149-157, 2014.
15. Biddlestone-Thorpe L, Marchi N, Guo K, Ghosh C, Janigro D, Valerie K, et al: Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Adv Drug Deliv Rev 64:605-613, 2012.
16. Black KL, Cloughesy T, Huang SC, Gobin YP, Zhou Y, Grous J, et al: Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 86:603-609, 1997.
17. Blanchette M, Pellerin M, Tremblay L, Lepage M, Fortin D: Real-time monitoring of gadolinium diethylenetriamine penta-acetic acid during osmotic blood-brain barrier disruption using magnetic resonance imaging in normal wistar rats. Neurosurgery 65:344-351, 2009.
18. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076-2080, 1994.
19. Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, et al: Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg 114:624-632, 2011.
20. Bregy A, Shah AH, Diaz MV, Pierce HE, Ames PL, Diaz D, et al: The role of Gliadel wafers in the treatment of highgrade gliomas. Expert Rev Anticancer Ther 13:1453-1461, 2013.
21. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012, 1995.
22. Cao X, Schoichet MS: Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials 20:329-339, 1999.
23. Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, et al: Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23:4127-4136, 2005.
24. Chacko AM, Li C, Pryma DA, Brem S, Coukos G, Muzykantov V: Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv 10:907-926, 2013.
25. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al: Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139-152, 2013.
26. Cheshier SH, Kalani MY, Lim M, Ailles L, Huhn SL, Weissman IL: A neurosurgeon's guide to stem cells, cancer stem cells, and brain tumor stem cells. Neurosurgery 65:237-250, 2009.
27. Debinski W, Tatter SB: Convection-enhanced delivery to achieve widespread distribution of viral vectors: predicting clinical implementation. Curr Opin Mol Ther 12:647-653, 2010.
28. Deeken JF, Löscher W: The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674, 2007.
29. del Burgo LS, Hernández RM, Orive G, Pedraz JL: Nanotherapeutic approaches for brain cancer management. Nanomedicine (Lond Print) 10:905-919, 2014.
30. Diaz RJ, McVeigh PZ, O'Reilly MA, Burrell K, Bebenek M, Smith C, et al: Focused ultrasound delivery of Raman nanoparticles across the blood-brain barrier: potential for targeting experimental brain tumors. Nanomedicine (Lond Print) 10:1075-1087, 2014.
31. Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, et al: Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res 1038:208-215, 2005.
32. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, et al: Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637-647, 2000.
33. Du J, Lu WL, Ying X, Liu Y, Du P, Tian W, et al: Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumorbearing animals. Mol Pharm 6:905-917, 2009.
34. el-Bacha RS, Minn A: Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand) 45:15-23, 1999.
35. Emerich DF, Snodgrass P, Pink M, Bloom F, Bartus RT: Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7). Brain Res 801:259-266, 1998.
36. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, et al: Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92:1936-1942, 2001.
37. Fadul CE, Wen PY, Kim L, Olson JJ: Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol 89:339-357, 2008.
38. Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, et al: MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res 74:598-608, 2014.
39. Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, et al: Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 74:157-163, 2010.
40. Gerber NU, Mynarek M, von Hoff K, Friedrich C, Resch A, Rutkowski S: Recent developments and current concepts in medulloblastoma. Cancer Treat Rev 40:356-365, 2014.
41. González-Mariscal L, Tapia R, Chamorro D: Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta 1778:729-756, 2008.
42. Groothuis DR, Warkne PC, Molnar P, Lapin GD, Mikhael MA: Effect of hyperosmotic blood-brain barrier disruption on transcapillary transport in canine brain tumors. J Neurosurg 72:441-449, 1990.
43. Gupta B, Levchenko TS, Torchilin VP: TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res 16:351-359, 2007.
44. Henson JW, Cordon-Cardo C, Posner JB: P-glycoprotein expression in brain tumors. J Neurooncol 14:37-43, 1992.
45. Huang TT, Hlavaty J, Ostertag D, Espinoza FL, Martin B, Petznek H, et al: Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Ther 20:544-551, 2013.
46. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N: Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24:12-20, 2005.
47. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA: Noninvasive opening of BBB by focused ultrasound. Acta Neurochir Suppl 86:555-558, 2003.
48. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA: Noninvasive MR imaging-guided focal opening of the bloodbrain barrier in rabbits. Radiology 220:640-646, 2001.
49. Hynynen K, McDannold N, Vykhodtseva N, Raymond S, Weissleder R, Jolesz FA, et al: Focal disruption of the bloodbrain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg 105:445-454, 2006.
50. Inamura T, Black KL: Bradykinin selectively opens bloodtumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 14:862-870, 1994.
51. Jalali S, Huang Y, Dumont DJ, Hynynen K: Focused ultrasound-mediated bbb disruption is associated with an increase in activation of AKT: experimental study in rats. BMC Neurol 10:114, 2010.
52. Jones PM, George AM: The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 61:682-699, 2004.
53. Jones RM, O'Reilly MA, Hynynen K: Transcranial passive acoustic mapping with hemispherical sparse arrays using CT-based skull-specific aberration corrections: a simulation study. Phys Med Biol 58:4981-5005, 2013.
54. Joshi S, Singh-Moon R, Wang M, Chaudhuri DB, Ellis JA, Bruce JN, et al: Cationic surface charge enhances early regional deposition of liposomes after intracarotid injection. J Neurooncol 120:489-497, 2014.
55. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162, 1976.
56. Juratli TA, Schackert G, Krex D: Current status of local therapy in malignant gliomas-a clinical review of three selected approaches. Pharmacol Ther 139:341-358, 2013.
57. Kaye EA, Chen J, Pauly KB: Rapid MR-ARFI method for focal spot localization during focused ultrasound therapy. Magn Reson Med 65:738-743, 2011.
58. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O: Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?. Cancer Treat Rev 30:415-423, 2004.
59. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK: Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 5:239-250, 2006.
60. Krauze MT, Forsayeth J, Yin D, Bankiewicz KS: Convectionenhanced delivery of liposomes to primate brain. Methods Enzymol 465:349-362, 2009.
61. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, et al: P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med 51:559-566, 2010.
62. Kunwar S: Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88:105-111, 2003.
63. Kunwar S, Pai LH, Pastan I: Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg 79:569-576, 1993.
64. Kutcher ME, Herman IM: The pericyte: cellular regulator of microvascular blood flow. Microvasc Res 77:235-246, 2009.
65. Lampidis TJ, Krishan A, Planas L, Tapiero H: Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Deliv 3:251-259, 1986.
66. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB: Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 16:117-131, 1990.
67. Lemasson B, Serduc R, Maisin C, Bouchet A, Coquery N, Robert P, et al: Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of lowmolecular-weight and macromolecular MR contrast media. Radiology 257:342-352, 2010.
68. Leweke F, Damian MS, Schindler C, Schachenmayr W: Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein. Pathol Res Pract 194:149-155, 1998.
69. Li XT, Ju RJ, Li XY, Zeng F, Shi JF, Liu L, et al: Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells. Oncotarget 5:6497-6511, 2014.
70. Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, et al: Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of hu-man glioblastoma multiforme. Acta Neuropathol 100:323-331, 2000.
71. Liu HL, Hua MY, Chen PY, Chu PC, Pan CH, Yang HW, et al: Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 255:415-425, 2010.
72. Liu LB, Xue YX, Liu YH: Bradykinin increases the permeability of the blood-tumor barrier by the caveolae-mediated transcellular pathway. J Neurooncol 99:187-194, 2010.
73. Marquet F, Tung YS, Teichert T, Ferrera VP, Konofagou EE: Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo. PLoS ONE 6: e22598, 2011.
74. Matsumoto T, Tani E, Kaba K, Shindo H, Miyaji K: Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 74:460-466, 1991.
75. McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS: Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 72:3652-3663, 2012.
76. McDannold N, Vykhodtseva N, Raymond S, Jolesz FA, Hynynen K: MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol 31:1527-1537, 2005.
77. Mei J, Cheng Y, Song Y, Yang Y, Wang F, Liu Y, et al: Experimental study on targeted methotrexate delivery to the rabbit brain via magnetic resonance imaging-guided focused ultrasound. J Ultrasound Med 28:871-880, 2009.
78. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, Mc-Donald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985-1000, 2002.
79. Nagpal S: The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma. Neurosurg Clin N Am 23:289-295, ix, 2012.
80. Nakagawa H, Groothuis D, Blasberg RG: The effect of graded hypertonic intracarotid infusions on drug delivery to experimental RG-2 gliomas. Neurology 34:1571-1581, 1984.
81. Nance EA, Woodworth GF, Sailor KA, Shih TY, Xu Q, Swaminathan G, et al: A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med 4:149ra119, 2012.
82. Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR: Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg 119:427-433, 2013.
83. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, et al: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580-1590, 1991.
84. Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, et al: Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267-275, 2005.
85. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Med 42:277-286, 1991.
86. Patel RR, Mehta MP: Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 13:1675-1683, 2007.
87. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, et al: Safety and feasibility of convectionenhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:1243-1253, 2005.
88. Pinzón-Daza ML, Salaroglio IC, Kopecka J, Garzòn R, Couraud PO, Ghigo D, et al: The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. J Cereb Blood Flow Metab 34:1258-1269, 2014.
89. Qin DX, Zheng R, Tang J, Li JX, Hu YH: Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys 19:1507-1510, 1990.
90. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6:2157-2165, 2000.
91. Rapoport SI: Advances in osmotic opening of the bloodbrain barrier to enhance CNS chemotherapy. Expert Opin Investig Drugs 10:1809-1818, 2001.
92. Rapoport SI: Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 20:217-230, 2000.
93. Rapoport SI, Hori M, Klatzo I: Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol 223:323-331, 1972.
94. Rapoport SI, Robinson PJ: Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann N Y Acad Sci 481:250-267, 1986.
95. Rascher G, Fischmann A, Kröger S, Duffner F, Grote EH, Wolburg H: Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol 104:85-91, 2002.
96. Reese TS, Karnovsky MJ: Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207-217, 1967.
97. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, et al: Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9:595-600, 1999.
98. Sage MR, Wilson AJ: The blood-brain barrier: an important concept in neuroimaging. AJNR Am J Neuroradiol 15:601-622, 1994.
99. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, et al: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27-35, 2003.
100. Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS, et al: Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 20(4):E14, 2006.
101. Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, et al: Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113:301-309, 2010.
102. Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW: Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 705:125-135, 1995.
103. Sarkar G, Curran GL, Sarkaria JN, Lowe VJ, Jenkins RB: Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain. PLoS ONE 9:e97655, 2014.
104. Shang X, Wang P, Liu Y, Zhang Z, Xue Y: Mechanism of low-frequency ultrasound in opening blood-tumor barrier by tight junction. J Mol Neurosci 43:364-369, 2011.
105. Sheikov N, McDannold N, Sharma S, Hynynen K: Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol 34:1093-1104, 2008.
106. Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K: Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol 30:979-989, 2004.
107. Sonabend AM, Carminucci AS, Amendolara B, Bansal M, Leung R, Lei L, et al: Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro Oncol 16:1210-1219, 2014.
108. Stupp R, Tonn JC, Brada M, Pentheroudakis G: High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5:v190-v193, 2010.
109. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234, 2006.
110. Tamai I, Tsuji A: Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 89:1371-1388, 2000.
111. Tanner PG, Holtmannspotter M, Tonn JC, Goldbrunner R: Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery 61:E880-E882, 2007.
112. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738, 1987.
113. Thomas H, Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Contr 10:159-165, 2003.
114. Tung YS, Marquet F, Teichert T, Ferrera V, Konofagou EE: Feasibility of noninvasive cavitation-guided blood-brain barrier opening using focused ultrasound and microbubbles in nonhuman primates. Appl Phys Lett 98:163704, 2011.
115. van Wamel A, Kooiman K, Emmer M, ten Cate FJ, Versluis M, de Jong N: Ultrasound microbubble induced endothelial cell permeability. J Control Release 116:e100-e102, 2006.
116. VanBavel E: Effects of shear stress on endothelial cells: possible relevance for ultrasound applications. Prog Biophys Mol Biol 93:374-383, 2007.
117. Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, et al: Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 58:343-347, 2006.
118. Warth A, Kröger S, Wolburg H: Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae. Acta Neuropathol 107:311-318, 2004.
119. Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G, Sontheimer H: Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nat Commun 5:4196, 2014.
120. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, et al: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64:125-137, 2003.
121. Weber FW, Floeth F, Asher A, Bucholz R, Berger M, Prados M, et al: Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88:93-103, 2003.
122. Wei KC, Chu PC, Wang HY, Huang CY, Chen PY, Tsai HC, et al: Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. PLoS ONE 8:e58995, 2013.
123. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 359:492-507, 2008.
124. Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman M, et al: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37:17-28, 1995.
125. Wolburg H, Lippoldt A: Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38:323-337, 2002.
126. Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G, Liebner S, Hamm S, et al: Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol 105:586-592, 2003.
127. Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H: Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 4:126, 2014.
128. Xi G, Robinson E, Mania-Farnell B, Vanin EF, Shim KW, Takao T, et al: Convection-enhanced delivery of nanodiamond drug delivery platforms for intracranial tumor treatment. Nanomedicine (Lond Print) 10:381-391, 2014.
129. Yu AS, McCarthy KM, Francis SA, McCormack JM, Lai J, Rogers RA, et al: Knockdown of occludin expression leads to diverse phenotypic alterations in epithelial cells. Am J Physiol Cell Physiol 288:C1231-C1241, 2005.
130. Zünkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, et al: Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 85:1056-1065, 1996.